AINMF
NETRAMARK HLDGS INC
stock OTC

https://preview.redd.it/sq6hdzo8bnpe1.jpg?width=598&format=pjpg&auto=webp&s=47c89fc3437a30206d0a450fd491601a41728f6b
TORONTO, March 10, 2025 /CNW/ - **NetraMark Holdings Inc. (the "Company" or "NetraMark")** (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is pleased to announce it has received aggregate proceeds of $1,853,054 from the exercise of 4,805,279 common share purchase warrants (the "Warrants") of the Company from December 12, 2024 to March 9, 2025.
This follows a previous round of warrant and stock option exercises that raised $1,161,000, as announced on December 12, 2024. In total, NetraMark has raised $3,014,054 from these exercises.
The Company now has 79,762,901 common shares issued and outstanding, following the exercise of these Warrants and stock options. This capital strengthens NetraMark's balance sheet, well positioning the Company to further execute on the continued development of its commercialization plans and support expansion of NetraMark's AI solutions, which empower pharmaceutical companies with actionable insights across protocol enrichment, covariate analysis, target product profile enhancement, market access, and precision medicine.
The Company extends its gratitude to its shareholders and partners for their continued confidence and support.
**About NetraAI**
In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success.  Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.
**About NetraMark**
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).

https://preview.redd.it/sq6hdzo8bnpe1.jpg?width=598&format=pjpg&auto=webp&s=47c89fc3437a30206d0a450fd491601a41728f6b
TORONTO, March 10, 2025 /CNW/ - **NetraMark Holdings Inc. (the "Company" or "NetraMark")** (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is pleased to announce it has received aggregate proceeds of $1,853,054 from the exercise of 4,805,279 common share purchase warrants (the "Warrants") of the Company from December 12, 2024 to March 9, 2025.
This follows a previous round of warrant and stock option exercises that raised $1,161,000, as announced on December 12, 2024. In total, NetraMark has raised $3,014,054 from these exercises.
The Company now has 79,762,901 common shares issued and outstanding, following the exercise of these Warrants and stock options. This capital strengthens NetraMark's balance sheet, well positioning the Company to further execute on the continued development of its commercialization plans and support expansion of NetraMark's AI solutions, which empower pharmaceutical companies with actionable insights across protocol enrichment, covariate analysis, target product profile enhancement, market access, and precision medicine.
The Company extends its gratitude to its shareholders and partners for their continued confidence and support.
**About NetraAI**
In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success.  Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.
**About NetraMark**
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).